MGI/SuperGen Estimate Dacogen Peak Sales Of $250 Mil.; Action Date Is Sept. 1
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
MGI and SuperGen estimate their myelodysplastic syndrome agent Dacogen has a market potential of $250 mil., SuperGen said July 21.